Incretin Atlas › Trials › REBUILDING-2 (RAY1225, NCT06893016)
REBUILDING-2 (RAY1225, NCT06893016)
RAY1225 · obesity
Design
- Molecule(s)
- RAY1225
- Population
- obesity
- Official title
- Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
- Phase
- 3
- Registry status
- recruiting · 2025-06 → 2026-06
- Participants
- 641
- Duration
- 52 weeks
- Registry
- NCT06893016
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 mg Q2W | obesity china | 52 | 641 | −22.3 % | −22.2 % | — | — | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (2)
- 9 mg Q2W · weight_tp · HKEX filing
9mg 组体重较基线降低 22.24%,经安慰剂校正后降低 20.46%
- 9 mg Q2W · weight_eff · HKEX filing
补充分析(假想策略)RAY1225 注射液 9mg 组体重较基线降低 22.30%,经安慰剂校正后降低 20.50%
Primary sources
- Raynovent / Zhongsheng. 众生药业 (002317.SZ) 关于控股子公司一类创新药RAY1225注射液减重III期临床试验获得顶线分析数据结果的公告 (2026-068) [HKEX filing]. 2026-10-08. Available from: http://static.cninfo.com.cn/finalpage/2026-10-09/1225597551.PDF
- ClinicalTrials.gov NCT06893016
How to cite this page
Medical Adviser's Group. Incretin Atlas: REBUILDING-2 (RAY1225, NCT06893016). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/rebuilding-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.